Company / R&D Expense
Aclaris Therapeutics, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$52.6M
FY2025
5-year range
$43.8M / $98.4M
FY2021-FY2025
Trend
-46.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 9 years, ranging from $15M in FY2017 to $98M in FY2024.
Based on SEC 10-K filings.
$53M in FY2025 with a 5-year CAGR of -2.9%.
Improved from $44M to $53M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -12.2%
- 5-Year CAGR
- -2.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.9%, indicating a declining trend.
- In FY2025, r&d expense decreased 46.5% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.6M | -46.5% |
| FY2024 | $98.4M | +124.6% |
| FY2023 | $43.8M | -43.7% |
| FY2022 | $77.8M | +77.6% |
| FY2021 | $43.8M | -28.0% |
| FY2020 | $60.8M | +69.9% |
| FY2019 | $35.8M | -41.2% |
| FY2018 | $60.8M | +296.6% |
| FY2017 | $15.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026